Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
37832
CAS Number:
1110813-31-4
Dacomitinib
Purity:
≥ 98 % (HPLC)
Synonym(s):
PF 00299804, ( E )- N -[4-[(3-chloro-4-fluorophényl)amino]-7-méthoxyquinazolin-6-yl]-4-(pipéridin-1-yl)but-2-énamide
Documents
$201.60 /50 mg
Taille
Request Bulk Quote
Informations sur le produit

Dacomitinib is a potent and selective irreversible inhibitor of the epidermal growth factor receptor (EGFR), primarily utilized in the treatment of non-small cell lung cancer (NSCLC). This compound is particularly effective against tumors with specific EGFR mutations, making it a valuable option for targeted therapy. Dacomitinib's unique mechanism of action allows for sustained inhibition of EGFR signaling pathways, which can lead to improved clinical outcomes in patients who have not responded to traditional therapies.

In addition to its application in oncology, Dacomitinib is being explored in combination therapies to enhance its efficacy and overcome resistance mechanisms in cancer treatment. Its favorable pharmacokinetic profile and ability to penetrate the blood-brain barrier also position it as a promising candidate for addressing central nervous system metastases. Researchers and healthcare professionals can leverage Dacomitinib's targeted action to optimize treatment regimens and improve patient quality of life.

Numéro CAS 
1110813-31-4
Formule moléculaire
C24H25ClFN5O2
Poids moléculaire 
469.95
Informations générales
Numéro CAS 
1110813-31-4
Formule moléculaire
C24H25ClFN5O2
Poids moléculaire 
469.95
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

Dacomitinib is widely utilized in research focused on:

  • Targeted Cancer Therapy: This compound is primarily used in the treatment of non-small cell lung cancer (NSCLC). By inhibiting specific pathways, it helps to block tumor growth and spread, offering a more effective treatment option compared to traditional chemotherapy.
  • Clinical Trials: Dacomitinib is frequently involved in clinical trials aimed at evaluating its efficacy and safety in various cancer types. Researchers benefit from its targeted action, which allows for more precise patient selection and potentially better outcomes.
  • Personalized Medicine: The use of Dacomitinib supports the growing field of personalized medicine, where treatments are tailored based on genetic markers. This approach enhances treatment effectiveness and minimizes side effects for patients with specific mutations.
  • Combination Therapies: It is often studied in combination with other therapeutic agents to improve treatment regimens. This strategy can lead to synergistic effects, increasing the overall effectiveness against resistant cancer types.
  • Research on Resistance Mechanisms: Dacomitinib is valuable in research aimed at understanding resistance mechanisms in cancer therapies. Insights gained can guide the development of next-generation inhibitors and improve treatment strategies.

Citations